Trial · NCT04885998
Adverse event totals24
The totals the trial posted for each group.
1 to 20 of 24
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 1 | 7 |
| Total, all-cause mortality | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 (EP) | 1 | 6 |
| Total, all-cause mortality | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 1 | 5 |
| Total, all-cause mortality | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 (EP) | 0 | 1 |
| Total, all-cause mortality | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | 1 | 3 |
| Total, all-cause mortality | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 (EP) | 1 | 1 |
| Total, all-cause mortality | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 (EP) | 2 | 4 |
| Total, all-cause mortality | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/B + AMG 404 | 0 | 8 |
| Total, other adverse events | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 7 | 7 |
| Total, other adverse events | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 (EP) | 1 | 6 |
| Total, other adverse events | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 5 | 5 |
| Total, other adverse events | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 (EP) | 0 | 1 |
| Total, other adverse events | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | 2 | 3 |
| Total, other adverse events | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 (EP) | 0 | 1 |
| Total, other adverse events | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 (EP) | 1 | 4 |
| Total, other adverse events | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/B + AMG 404 | 8 | 8 |
| Total, serious adverse events | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 5 | 7 |
| Total, serious adverse events | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 (EP) | 1 | 6 |
| Total, serious adverse events | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 3 | 5 |
| Total, serious adverse events | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 (EP) | 0 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04885998/event-totals